Boaz Weinstein’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Boaz Weinstein’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-250,000	Closed	-$33.6K	–	296
2024 Q4	$33.6K	Hold	250,000	–	–	﹤0.01%	202
2024 Q3	$29.3K	Hold	250,000	–	–	﹤0.01%	240
2024 Q2	$30.1K	Hold	250,000	–	–	﹤0.01%	269
2024 Q1	$35.8K	Hold	250,000	–	–	﹤0.01%	274
2023 Q4	$44.4K	Hold	250,000	–	–	﹤0.01%	331
2023 Q3	$57.5K	Hold	250,000	–	–	﹤0.01%	367
2023 Q2	$47.8K	Hold	250,000	–	–	﹤0.01%	417
2023 Q1	$41.3K	Buy	+250,000	New	+$38.9K	﹤0.01%	565

Boaz Weinstein's BLACR Position: Q1 2025 in Review

Boaz Weinstein sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 250,000 shares — an estimated $33.6K sold.

Boaz Weinstein first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $57.5K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Boaz Weinstein reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Boaz Weinstein sold 250,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $33.6K.
Boaz Weinstein first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
Boaz Weinstein's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $57.5K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Saba Capital Management's 13F filing for Q1 2025, filed 15 May 2025.